Low-Dose Radiation Therapy Is NOT Recommended for Advanced Arthritis
Low-dose radiation therapy (LDRT) should not be used for the treatment of advanced arthritis based on current evidence showing no significant benefit over placebo and the availability of established, evidence-based alternatives.
Why LDRT Should Be Avoided
The most recent and highest-quality evidence demonstrates that LDRT provides no meaningful benefit over sham treatment for osteoarthritis:
- A 2025 systematic review and meta-analysis of 12 studies (1,750 participants) found LDRT showed no significant benefit over sham treatment in reducing pain (P = 0.13) or improving function (P = 0.22) 1
- Adverse events were significantly more common with LDRT (RR: 1.44; 95% CI: 1.08-1.92), including nail reactions (RR: 2.24) 1
- The evidence certainty was rated as high for adverse events but only moderate for pain and functional outcomes 1
- The authors concluded LDRT "should remain investigational reserved for research or select refractory cases" 1
A 2026 expert perspective in Arthritis & Rheumatology reinforces this position, noting that "the evidence base for such recommendations is sparse" and that "rheumatologists should be circumspect about suggesting it for their patients" unless further randomized double-blind controlled trials are conducted 2.
What Should Be Done Instead
For Inflammatory Arthritis (Early Disease)
If this is inflammatory arthritis rather than osteoarthritis, the approach is entirely different:
- Refer to rheumatology within 6 weeks of symptom onset 3
- Start disease-modifying antirheumatic drugs (DMARDs) within 3 months, with methotrexate as the anchor drug 3
- NSAIDs at minimum effective dose for shortest duration after cardiovascular/renal/GI risk assessment 3
- Systemic glucocorticoids only as temporary (<6 months) adjunctive therapy at lowest dose 3
For Advanced Osteoarthritis
The 2023 ACR/AAHKS guidelines provide clear direction 4:
Do not delay total joint arthroplasty (TJA) for additional nonoperative treatments (physical therapy, NSAIDs, injections) if:
- Patient has moderate-to-severe radiographic OA
- Moderate-to-severe pain or functional loss
- Failed ≥1 appropriate nonoperative therapy trial
- Shared decision-making indicates surgery is appropriate
Proceed directly to TJA without arbitrary waiting periods 4
The only conditional delays recommended are for:
- Nicotine cessation or reduction (conditionally recommended)
- Improved glycemic control in diabetes (conditionally recommended, though no specific threshold identified)
- NOT for obesity alone - weight loss encouraged but not a rigid threshold for surgery 4
For Non-Surgical Candidates with OA
The 2020 ACR/Arthritis Foundation OA guidelines 5 recommend:
- Exercise (walking, strengthening, neuromuscular training, aquatic)
- Weight management
- NSAIDs at minimum effective dose
- Intra-articular glucocorticoid injections
- Bracing (tibiofemoral brace for TF OA strongly recommended)
- Topical NSAIDs
Critical Pitfalls to Avoid
Do not pursue LDRT based on observational studies alone - The retrospective studies showing benefit 6, 7 are contradicted by higher-quality placebo-controlled trials 1
Recognize the powerful placebo effect in OA - The expert perspective notes the placebo effect is so potent in OA that it may itself be considered "active" therapy 2
Do not delay definitive surgical treatment in appropriate candidates to pursue unproven therapies like LDRT 4
Radiation carries real risks even at low doses, particularly cumulative exposure and potential malignancy risk, which must be weighed against lack of proven benefit 1
The Evidence Contradiction
While some studies suggest benefit 6, 8, 7, 9, these are primarily:
- Retrospective analyses without sham controls
- Single-arm studies susceptible to placebo effects
- Smaller trials with methodological limitations
The highest-quality evidence from 2025 meta-analysis with moderate-to-high certainty ratings clearly shows no benefit over sham 1, and this should guide clinical decision-making prioritizing patient safety and evidence-based care.